Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Our new In the Zone on targeted MS imaging is now live! Check it out!

An interview with Chad Briscoe and Nico van der Merbel on large molecules and mass spectrometry

17 May 2018
Interviews Large molecules MS (LC–MS/MS, HRMS, IMS)

In this interview, Nico and Chad (PRA Health Sciences; NC, USA) discuss the advantages, disadvantages and challenges they face with the technologies they utilize, before predicting what the future holds for the field.

Button Text

Related tags

LCMS mass spectrometry PRA
Previous article Next article

Related articles

8 JAN 2019 INTERVIEWS
An interview with Shane Needham (Alturas Analytics) on the development and validation of assays
20 APR 2018 INTERVIEWS
Active drug quantification by hybrid LC–MS: an interview with Roland Staack & Gregor Jordan
25 JUN 2019 INTERVIEWS
Advancing mass spectrometry technologies: an interview with Neil Walsh
23 APR 2018 INTERVIEWS
LC–MS and ADA analysis: an interview with Marco Michi
9 MAY 2022 BIOANALYSIS RISING STAR AWARD
Bioanalysis Rising Star Award finalist: Brendan Powers
22 JUN 2020 INTERVIEWS
Practical considerations for mass spectrometry with Timothy Garrett
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone